文献速递生殖医学

芳香化酶抑制剂治疗男性不育的临床应用

Clinical application of aromatase inhibitors to treat male infertility.
PubMed 文献 · Hum Reprod Update · 2021-01-01

本文为叙述性综述,基于过去四十年MEDLINE/PubMed和EMBASE文献,总结芳香化酶抑制剂(如来曲唑、阿那曲唑)治疗男性不育的药理机制、临床试验、疗效影响因素及副作用,指出其可抑制雌二醇生成、升高睾酮和FSH并改善精液参数,但多为超说明书经验性用药,CYP19A1多态性可能影响疗效,机制仍需进一步研究。

要点

  • 非甾体芳香化酶抑制剂可显著抑制雌二醇生成,升高睾酮和FSH,改善不育男性精液参数。
  • 肥胖相关低促性腺激素性性腺功能减退症状可经芳香化酶抑制剂治疗改善。
  • CYP19A1单核苷酸多态性及TTTAn重复多态性可能影响激素谱、精液质量及芳香化酶抑制剂疗效。

核心结论

  • 芳香化酶抑制剂治疗男性不育已超说明书经验性应用数十年,本综述总结了目标患者、剂量、疗程及副作用,但全面理解其作用机制仍需进一步研究。

研究设计与样本

  • 叙述性综述,检索MEDLINE/PubMed和EMBASE中过去四十年关于芳香化酶抑制剂治疗男性不育的文献。

主要发现

  • 临床研究表明芳香化酶抑制剂尤其是非甾体来曲唑和阿那曲唑可显著抑制雌二醇生成及其对下丘脑-垂体-性腺轴的负反馈,使不育男性睾酮和FSH生成增加并改善精液参数。
  • 大型调查提示肥胖可导致可育和不育男性出现性腺功能减退症状如精液质量下降和性功能减退,芳香化酶抑制剂治疗可改善这些症状。
  • 芳香化酶基因CYP19A1多态性包括单核苷酸多态性和四核苷酸TTTA重复多态性(TTTAn)影响男性低促性腺激素性性腺功能减退和不育患者的激素谱、精液质量及芳香化酶抑制剂疗效。
  • 芳香化酶抑制剂治疗男性不育的副作用多样,但多数轻微且耐受良好。

关键数值与推荐

  • 非甾体来曲唑和阿那曲唑可显著抑制雌二醇生成并改善精液参数。
  • CYP19A1单核苷酸多态性和TTTAn重复多态性可能影响芳香化酶抑制剂疗效。

临床怎么用

  • 芳香化酶抑制剂治疗男性不育已超说明书经验性应用数十年,本综述总结了目标患者、剂量、疗程和副作用,但全面理解其作用机制仍需进一步研究。

局限性

  • 缺乏大规模随机对照研究和基础研究,芳香化酶抑制剂治疗男性不育的疗效和安全性仍存争议。
  • 全面理解芳香化酶抑制剂作用机制仍需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Infertility affects 15% of men and contributes to nearly half of all cases of infertility. Infertile men usually have impaired spermatogenesis, presenting as azoospermia or various degrees of asthenospermia and oligozoospermia. Spermatogenesis is a complex and coordinated process, which is under precise modulation by the hypothalamic-pituitary-gonadal (HPG) axis. An aberrant hormone profile, especially an imbalance between testosterone (T) and estradiol (E2), plays an essential role in male infertility. In the male, E2 is produced mainly from the conversion of T by the aromatase enzyme. Theoretically, reducing an abnormally elevated T:E2 ratio using aromatase inhibitors (AIs) could restore the balance between T and E2 and optimize the HPG axis to support spermatogenesis. For decades, AIs have been used to treat male infertility empirically. However, owing to the lack of large-scale randomized controlled studies and basic research, the treatment efficacy and safety of AIs in male infertility remain controversial. Therefore, there is a need to summarize the clinical trials and relevant basic research on the application of AIs in the treatment of male infertility. OBJECTIVE AND RATIONALE: In this narrative review, we summarized the application of AIs in the treatment of male infertility, including the pharmacological mechanisms involved, clinical trials focused on patients with different types of infertility, factors affecting treatment efficacy and the side-effects. SEARCH METHODS: A literature search was performed using MEDLINE/PubMed and EMBASE, focusing on publications in the past four decades concerning the use of AIs for treating male infertility. The search terms included AI, male infertility, letrozole, anastrozole, testolactone, azoospermia, oligozoospermia, aromatase polymorphisms, obesity and antiestrogens, in various combinations. OUTCOMES: Clinical studies demonstrate that AIs, especially nonsteroidal letrozole and anastrozole, could significantly inhibit the production of E2 and its negative feedback on the HPG axis, resulting in increased T and FSH production as well as improved semen parameters in infertile men. Large-scale surveys suggest that obesity may result in symptoms of hypogonadism in both fertile and infertile males, such as decreased semen quality and attenuated sexual function, which can be improved by AIs treatment. Polymorphisms of the aromatase gene CYP19A1, including single nucleotide polymorphisms and tetranucleotide TTTA repeats polymorphism (TTTAn), also influence hormone profiles, semen quality and treatment efficacy of AIs in male hypogonadotropic hypogonadism and infertility. The side-effects of AIs in treating male infertility are various, but most are mild and well tolerated. WIDER IMPLICATIONS: The application of AIs in treating male infertility has been off-label and empirical for decades. This narrative review has summarized the target patients, dose, treatment duration and side-effects of AIs. Polymorphisms of CYP19A1 that may affect AIs treatment efficacy were also summarized, but a full understanding of the mechanisms involved in AIs action requires further study.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Yang C, Li P, Li Z, et al. Clinical application of aromatase inhibitors to treat male infertility. Hum Reprod Update. 2021. PMID: 34871401. doi:10.1093/humupd/dmab036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。